Funding
Pathos closes a $237 million Series E; its next proof still has to come from the clinic
Bristol Myers Squibb led the financing at an approximately $3 billion post-money valuation, according to Pathos. The company plans to scale its AI platform and advance its drug pipeline, including JSKN016 toward registrational studies.